Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Ipsen |
---|---|
Information provided by: | Ipsen |
ClinicalTrials.gov Identifier: | NCT00447876 |
This study will investigate the hypothesis that the analgesic and inflammatory effect of a single injection of Dysport (200 MU) induces a significant reduction of symptoms in chronic cases of plantar fasciitis.
Condition | Intervention | Phase |
---|---|---|
Chronic Plantar Fasciitis |
Drug: Botulinum type A toxin (Dysport®) |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Double-Blind, Placebo-Controlled, Randomised, Multicentre Study on the Efficacy and Safety of a Single Injection of Botulinum Toxin A (200 Units Dysport®) in the Treatment of Chronic Plantar Fasciitis |
Estimated Enrollment: | 40 |
Study Start Date: | July 2005 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Botulinum type A toxin (Dysport®)
Placebo: 0,9% sodium chloride, 2 ml Drug: Botulinum type A toxin (Dysport®) 200 Units / 2 ml injected at the root of the plantar fascia
|
2: Placebo Comparator |
Drug: Botulinum type A toxin (Dysport®)
Placebo: 0,9% sodium chloride, 2 ml Drug: Botulinum type A toxin (Dysport®) 200 Units / 2 ml injected at the root of the plantar fascia
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ipsen Recruitment Enquiries | clinical.trials@ipsen.com |
Germany | |
University Hospital Charite, Campus Virchow, Musculoskeletal Centre, Orthopedic Clinic | Recruiting |
Berlin, Germany, 13353 | |
Orthopedic Practice | Recruiting |
Weiden, Germany, 92637 | |
Orthopedic Practice | Recruiting |
Karlsruhe, Germany, 76133 | |
Klinik für Orthopädie und Rheumatologie, Universitätsklinikum Gießen und Marburg GmbH | Recruiting |
Standort Marburg, Germany | |
Orthopedic Practice Biberburg | Recruiting |
Berlin, Germany, 14089 | |
Orthocentre Munich | Terminated |
Munich, Germany, 81547 |
Study Director: | Bert Van Eijk, MD | Ipsen |
Responsible Party: | Ipsen ( Bert Van Eijk ) |
Study ID Numbers: | A-94-52120-100 |
Study First Received: | March 13, 2007 |
Last Updated: | October 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00447876 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Fasciitis, Plantar Botulinum Toxins Musculoskeletal Diseases |
Fasciitis Botulinum Toxin Type A Foot Diseases |
Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents Pharmacologic Actions |